[{"id":"52814cd1-a8ab-4fbc-9958-b65faef07451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05599412","created_at":"2022-10-31T13:56:49.808Z","updated_at":"2025-02-25T14:41:38.018Z","phase":"","brief_title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","source_id_and_acronym":"NCT05599412","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-02-14"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"cec10506-6390-45ed-9785-1b2e4ff57e38","acronym":"QLMA-NSCLC-IIT-001","url":"https://clinicaltrials.gov/study/NCT06697990","created_at":"2025-02-26T13:42:05.793Z","updated_at":"2025-02-26T13:42:05.793Z","phase":"Phase 2","brief_title":"Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients","source_id_and_acronym":"NCT06697990 - QLMA-NSCLC-IIT-001","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-11-20"},{"id":"f032cb75-7b0a-4fb8-9e69-7cf2c851ab56","acronym":"COMLORLA","url":"https://clinicaltrials.gov/study/NCT06690541","created_at":"2025-02-26T13:54:01.529Z","updated_at":"2025-02-26T13:54:01.529Z","phase":"","brief_title":"Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC","source_id_and_acronym":"NCT06690541 - COMLORLA","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 10/31/2030","study_completion_date":" 10/31/2030","last_update_posted":"2024-11-15"},{"id":"55fca2cd-0dc1-47d8-86f5-df409157addc","acronym":"ALKALINE","url":"https://clinicaltrials.gov/study/NCT04127110","created_at":"2021-01-18T20:09:41.572Z","updated_at":"2025-02-25T12:37:27.279Z","phase":"Phase 2","brief_title":"Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients","source_id_and_acronym":"NCT04127110 - ALKALINE","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-11-05"},{"id":"2a11f2ce-d7a1-4499-9adf-7f2d5fda7036","acronym":"ROSALINE","url":"https://clinicaltrials.gov/study/NCT04551495","created_at":"2021-01-18T21:45:49.585Z","updated_at":"2024-07-02T16:34:26.568Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)","source_id_and_acronym":"NCT04551495 - ROSALINE","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • letrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"41b01b41-ccaf-44d0-9901-ee4360f0dfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828303","created_at":"2023-04-25T14:03:37.911Z","updated_at":"2024-07-02T16:35:10.118Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05828303","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-04-11"},{"id":"eaa7905b-c46a-428c-a893-85ea9fe3af9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441956","created_at":"2022-07-01T20:56:47.697Z","updated_at":"2024-07-02T16:35:10.474Z","phase":"Phase 1","brief_title":"TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05441956","lead_sponsor":"Shenzhen TargetRx, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e deulorlatinib (TGRX-326)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-10"},{"id":"a6c847c7-a1bd-4b36-aa8d-0987c59a806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04979988","created_at":"2021-07-28T19:52:27.204Z","updated_at":"2024-07-02T16:35:11.225Z","phase":"","brief_title":"Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients","source_id_and_acronym":"NCT04979988","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 12/09/2021","primary_completion_date":" 12/09/2021","study_txt":" Completion: 12/09/2021","study_completion_date":" 12/09/2021","last_update_posted":"2024-04-05"},{"id":"a005015e-d5d3-4c57-83b2-3093dd60eeae","acronym":"TOTEM","url":"https://clinicaltrials.gov/study/NCT04772235","created_at":"2021-02-26T13:55:19.583Z","updated_at":"2025-02-25T14:29:55.997Z","phase":"Phase 1","brief_title":"Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients","source_id_and_acronym":"NCT04772235 - TOTEM","lead_sponsor":"Instituto Oncológico Dr Rosell","biomarkers":" ALK • MET • ROS1 • HAVCR2 • NTRK","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR T790M","tags":["ALK • MET • ROS1 • HAVCR2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/11/2022","start_date":" 02/11/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-03"},{"id":"dcc86dfa-5f1f-487e-97bd-3b553b98917f","acronym":"STARTRK-NG","url":"https://clinicaltrials.gov/study/NCT02650401","created_at":"2021-01-18T12:54:05.938Z","updated_at":"2024-07-02T16:35:12.285Z","phase":"Phase 1/2","brief_title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","source_id_and_acronym":"NCT02650401 - STARTRK-NG","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-29"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"b0bd248a-bd03-4ed3-b6a6-a8c5210d9df6","acronym":"REPOSE","url":"https://clinicaltrials.gov/study/NCT06315010","created_at":"2024-03-18T15:22:57.128Z","updated_at":"2024-07-02T16:35:14.368Z","phase":"Phase 2","brief_title":"REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis","source_id_and_acronym":"NCT06315010 - REPOSE","lead_sponsor":"MedSIR","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-03-18"},{"id":"0db68b48-63b4-415c-9bee-7380074c53b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396859","created_at":"2022-05-31T12:54:45.824Z","updated_at":"2024-07-02T16:35:14.538Z","phase":"Phase 1","brief_title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT05396859","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • RUNX1 • MAPK1 • NTRK • MAPK3","pipe":" | ","alterations":" TP53 mutation • NTRK expression","tags":["TP53 • RUNX1 • MAPK1 • NTRK • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-15"},{"id":"78482e2a-4e36-4c51-a81b-de4897029fc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004116","created_at":"2021-08-13T12:53:24.897Z","updated_at":"2024-07-02T16:35:15.181Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer","source_id_and_acronym":"NCT05004116","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-03-12"},{"id":"5452d7d5-025f-4999-aea4-518221d84eaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04362072","created_at":"2021-01-18T21:05:08.971Z","updated_at":"2024-07-02T16:35:15.535Z","phase":"Phase 4","brief_title":"Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04362072","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 06/25/2024","primary_completion_date":" 06/25/2024","study_txt":" Completion: 06/25/2024","study_completion_date":" 06/25/2024","last_update_posted":"2024-03-08"},{"id":"9f0a2252-2d03-40ea-9677-2060190e337e","acronym":"ARROS-1","url":"https://clinicaltrials.gov/study/NCT05118789","created_at":"2021-11-12T13:53:34.949Z","updated_at":"2024-07-02T16:35:15.663Z","phase":"Phase 1/2","brief_title":"A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","source_id_and_acronym":"NCT05118789 - ARROS-1","lead_sponsor":"Nuvalent Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zidesamtinib (NVL-520)"],"overall_status":"Recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-03-08"},{"id":"6e624d98-871e-49ea-8880-cb9fc71ea587","acronym":"ORAKLE","url":"https://clinicaltrials.gov/study/NCT04111705","created_at":"2021-01-18T20:06:14.100Z","updated_at":"2024-07-02T16:35:15.855Z","phase":"Phase 2","brief_title":"Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04111705 - ORAKLE","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-07"},{"id":"0af4f6ed-3aa2-4b1d-8872-fccfa3bf15e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607188","created_at":"2021-01-18T17:43:59.726Z","updated_at":"2024-07-02T16:35:16.280Z","phase":"Phase 1","brief_title":"Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer","source_id_and_acronym":"NCT03607188","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • alkotinib (ZG0418)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 10/18/2018","start_date":" 10/18/2018","primary_txt":" Primary completion: 10/17/2022","primary_completion_date":" 10/17/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2024-03-06"},{"id":"572a4851-2844-4d71-983a-e125903b898b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282991","created_at":"2024-02-28T22:32:48.726Z","updated_at":"2024-07-02T16:35:17.489Z","phase":"","brief_title":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled","source_id_and_acronym":"NCT06282991","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/18/2021","primary_completion_date":" 01/18/2021","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2024-02-28"}]